# Rhapsido recommended in 2026 International Urticaria Guideline for all patients who remain symptomatic after H1-antihistamine treatment.

*biotech · news · 2026-04-27 · The Manila Times*

## Key points

- The European Commission has approved Rhapsido (remibrutinib) as the first oral targeted CSU treatment.
- REMIX-1 and REMIX-2 studies showed Rhapsido provides significant CSU symptom improvement as early as Week 1.
- Rhapsido requires no laboratory monitoring and has no liver safety concerns in clinical trials.
- Rhapsido is newly recommended in the 2026 International Urticaria Guideline for antihistamine-refractory CSU.

**Companies:** Novartis
**Countries:** Germany, United States, China

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/27/tmt-newswire/globenewswire/novartis-rhapsido-receiveseuropean-commissionapproval-asfirstoral-targeted-treatment-for-chronic-spontaneous-urticaria/2328963)

---

Canonical: https://newsio.io/n/83b4edb5-4f2c-434a-9de4-47ece72b22ea/rhapsido-recommended-in-2026-international-urticaria-guideline-for-all-patients
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works